FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a method of treating a disease or condition associated with excessive expression of IAP by initiating apoptosis and/or increasing the sensitivity of said cancer cell to apoptosis, administering to mammal an IAP inhibitor of general formula (I).
EFFECT: disclosed are IAP inhibitors.
18 cl, 2 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IAP INHIBITORS | 2013 |
|
RU2593259C2 |
| IAP INHIBITORS | 2005 |
|
RU2401840C2 |
| IMIDAZOPYRIDINE IAP INHIBITORS | 2007 |
|
RU2466131C2 |
| IAP INHIBITORS | 2008 |
|
RU2491276C2 |
| IAP INHIBITORS | 2006 |
|
RU2451025C2 |
| COMPOUNDS BINDING BTR DOMAIN OF IAP PROTEINS | 2007 |
|
RU2472780C2 |
| COMPOUNDS BOUND WITH BIR DOMAIN OF IAP | 2007 |
|
RU2446170C2 |
| BIR DOMAIN IAP BINDING COMPOUNDS | 2011 |
|
RU2567544C2 |
| TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DESTROYERS | 2017 |
|
RU2797244C2 |
| BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS OF IMPLEMENTATION | 2013 |
|
RU2649975C2 |
